Formycon AG: Strategic Advancements and Market Opportunities Drive Buy Rating
Yi Chen has assigned a Buy rating to Formycon AG, citing the successful launch of its ranibizumab biosimilar, FYB201, in Europe, which offers advantages like reduced preparation time. Regulatory challenges for competitor Xbrane Biopharma enhance Formycon's position as Sandoz prepares to market FYB201 in the U.S. by mid-2026. A strategic settlement with Regeneron for FYB203 allows for a potential U.S. launch in late 2026. Anticipated results from the Dahlia trial of FYB206 in early 2026 could further strengthen Formycon's growth prospects.
Yi Chen has given his Buy rating due to a combination of factors including the successful launch of Formycon’s ranibizumab biosimilar, FYB201, in Europe. This product, introduced in a pre-filled syringe format, offers significant advantages such as reduced preparation time and increased dosing accuracy, which could enhance its market penetration and drive royalty revenues for Formycon. Additionally, the recent regulatory challenges faced by a competitor, Xbrane Biopharma, in the U.S. position Formycon favorably as its partner, Sandoz, prepares to market FYB201 in the U.S. by the first half of 2026.
Furthermore, Formycon’s strategic settlement regarding FYB203 with Regeneron Pharmaceuticals paves the way for its U.S. launch in the fourth quarter of 2026, potentially earlier. This settlement resolves patent disputes and grants exclusive commercial rights to Valorum Biologics in the U.S. and Canada. Lastly, the anticipated results from the Dahlia trial of FYB206, expected in the first quarter of 2026, could further bolster Formycon’s pipeline, enhancing its long-term growth prospects. These developments collectively support Yi Chen’s optimistic outlook and Buy rating for Formycon AG.
